DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rjxpww/global_market) has announced the addition of the "Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022" report to their offering.
The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market. However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market.
North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs.
Bisphosphonates are the most commonly prescribed medication for treatment and prevention of osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Market Synopsis
Chapter 3 Porter's Five Forces Analysis
Chapter 4 Industry Overview
Chapter 5 Global Market Size and Forecast
Chapter 6 Market Size and Forecast by Drug Type
Chapter 7 Market Size and Forecast by Geography
Chapter 8 Competitive Scenario
Chapter 9 Company Profiles
- Actavis plc
- Amgen, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer, Inc
- Teva Pharmaceutical Industries Ltd.
For more information visit http://www.researchandmarkets.com/research/rjxpww/global_market